Wealth Enhancement Advisory Services LLC Buys 120,192 Shares of Bristol-Myers Squibb (NYSE:BMY)

Wealth Enhancement Advisory Services LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 34.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 470,526 shares of the biopharmaceutical company's stock after acquiring an additional 120,192 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Bristol-Myers Squibb were worth $26,613,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. PKO Investment Management Joint Stock Co acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $905,000. Centaurus Financial Inc. grew its stake in shares of Bristol-Myers Squibb by 11.5% in the fourth quarter. Centaurus Financial Inc. now owns 12,175 shares of the biopharmaceutical company's stock valued at $689,000 after acquiring an additional 1,256 shares in the last quarter. Anchor Pointe Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $234,000. Mattson Financial Services LLC grew its stake in shares of Bristol-Myers Squibb by 3,318.2% in the fourth quarter. Mattson Financial Services LLC now owns 752 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 730 shares in the last quarter. Finally, Wood Tarver Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $38,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded up $0.41 on Friday, reaching $48.26. The company had a trading volume of 20,756,575 shares, compared to its average volume of 13,069,665. The business's 50-day moving average is $50.49 and its 200 day moving average is $55.39. The stock has a market capitalization of $98.21 billion, a PE ratio of -10.92, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the business earned ($4.40) EPS. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.14%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, Jefferies Financial Group decreased their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and a consensus target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.